Beta Bionics Inc. kicked off the new year with plans for an initial public offering of 7.5 million shares “as soon as practicable.” Expected to be priced at $14 to $16 per share, the IPO would gross $105 million to $120 million for the insulin delivery device maker. Read More
With key officials yet to be confirmed at the U.S. Department of Health and Human Services, the acting secretary imposed an immediate pause throughout the department on publicly issuing any document or communication without first getting it approved by a presidential appointee. Read More
In a boon for companies developing brain-computer interface (BCI) technologies, researchers have used a BCI and artificial intelligence to restore touch sensations in a bionic arm. Read More
The backlog of requests for Medicare national coverage analyses is a matter of record, but a new analysis highlights how deep that backlog runs. CMS declared it will review a petition from Impulse Dynamics to consider coverage of cardiac contractility modulation, responding to a request the company filed more than two and a half years ago. Read More
Med-tech stocks experienced a turbulent year of ups and downs in 2024, as the BioWorld Med-Tech Stock Index saw lows of almost 15% and gains of nearly 5% before closing the year up 0.21%. This modest rebound follows consecutive declines of 4.44% in 2023 and a steep drop of 39.58% in 2022.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Lunit.ai, Medskin Solutions, OGT, Vantis Vascular. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accuray, Becton, Dickinson and Co, Biosero, Danaher, Dassault Systèmes, Eleszto Genetika, Exthera Medical, GPC Bio, Global Process Concept, Leica, Medidata, Merck, Milleporesigma, Molecular Instruments, Opentrons, Pictor Biotech, Solarbiotech, Tigermed. Read More
